Brokerages Expect Neon Therapeutics Inc (NASDAQ:NTGN) Will Announce Earnings of -$0.63 Per Share

Equities analysts predict that Neon Therapeutics Inc (NASDAQ:NTGN) will announce earnings of ($0.63) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Neon Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.80). Neon Therapeutics reported earnings of ($0.67) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 6%. The business is scheduled to issue its next quarterly earnings results on Monday, November 11th.

According to Zacks, analysts expect that Neon Therapeutics will report full year earnings of ($2.55) per share for the current year, with EPS estimates ranging from ($3.18) to ($1.85). For the next year, analysts expect that the firm will report earnings of ($2.31) per share, with EPS estimates ranging from ($4.17) to ($1.42). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.01).

NTGN has been the topic of several research reports. Morgan Stanley reduced their price objective on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a research note on Tuesday, July 16th. ValuEngine raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Mizuho set a $21.00 price objective on shares of Neon Therapeutics and gave the company a “buy” rating in a research note on Monday, July 1st. Zacks Investment Research cut shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. Finally, HC Wainwright boosted their price target on shares of Neon Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $14.43.

Several institutional investors have recently made changes to their positions in NTGN. Marshall Wace North America L.P. bought a new stake in Neon Therapeutics during the 1st quarter valued at $49,000. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Neon Therapeutics by 100.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after buying an additional 5,000 shares during the last quarter. Rhumbline Advisers bought a new stake in Neon Therapeutics during the 1st quarter valued at $78,000. Bank of New York Mellon Corp raised its holdings in Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after buying an additional 2,905 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after buying an additional 6,493 shares during the last quarter. 69.53% of the stock is owned by institutional investors.

Shares of NASDAQ NTGN traded down $0.01 during midday trading on Monday, hitting $2.39. The company’s stock had a trading volume of 100,700 shares, compared to its average volume of 162,154. The company’s fifty day simple moving average is $3.85. Neon Therapeutics has a one year low of $2.31 and a one year high of $12.69. The company has a quick ratio of 7.30, a current ratio of 6.13 and a debt-to-equity ratio of 0.12. The stock has a market cap of $68.11 million, a price-to-earnings ratio of -0.43 and a beta of 1.62.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

See Also: Correction

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit